Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma

Leukemia and Lymphoma

Volumn 48, Issue 12, 2007, Pages 2338-2344

  Baz, Rachid ^a   Fanning, Suzanne ^b   Kunkel, Lori ^c   Gaballa, Sameh ^d   Karam, Mary Ann ^a   Reed, Janice ^a   Kelly, Megan ^a   Hussein, Mohamad ^e  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b US Oncology   (United States)

^c Proteolix Inc   (United States)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CD20; Clonotypic B cells; Maintenance therapy; Melphalan prednisone; Multiple myeloma; Rituximab

Indexed keywords

BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMID; CD20 ANTIGEN; ERYTHROPOIETIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LENALIDOMIDE; MELPHALAN; NARCOTIC ANALGESIC AGENT; OPIATE; PAMIDRONIC ACID; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE DISEASE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGLOBULIN DEFICIENCY; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; PROSPECTIVE STUDIES;

EID: 37149002438     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701644330     Document Type: Article

References (18)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, M. (2007) Cancer statistics, 2007. CA Cancer J Clin, 57, pp. 43-66.
2. Alexanian, R., Haut, A., Khan, A. U., Lane, M., McKelvey, E. M. and Migliore, P. J. (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA, 208, pp. 1680-1685.
3. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials (1998) Myeloma Trialists' Collaborative Group. J Clin Oncol, 16, pp. 3832-3842.
4. Facon, T., Mary, J., Hulin, C., Benboubker, L., Attal, M. and Renaud, M. (2005) Major Superiority of melphalan - prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood (Suppl.), 106, p. 780.
5. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V. and Callea, V. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet, 367, pp. 825-831.
6. Miguel, J F San, Garcia-Sanz, R., Gonzalez, M. and Orfao, A. (1995) Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol, 8, pp. 735-759.
7. Miguel, J F San, Gonzalez, M., Gascon, A., Moro, M. J., Hernandez, J. M. and Ortega, F. (1991) Immunophenotypic heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol, 77, pp. 185-190.
8. Robillard, N., Avet-Loiseau, H., Garand, R., Moreau, P., Pineau, D. and Rapp, M. J. (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102, pp. 1070-1071.
9. Treon, S. P., Pilarski, L. M., Belch, A. R., Kelliher, A., Preffer, F. I. and Shima, Y. (2002) CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications. J Immunother, 25, pp. 72-81.
10. Zojer, N., Kirchbacher, K., Vesely, M., Hubl, W. and Ludwig, H. (2006) Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma, 47, pp. 1103-1109.
11. Cook, J. R., Hsi, E. D., Worley, S., Tubbs, R. R. and Hussein, M. (2006) Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol, 125, pp. 615-624.
12. Pilarski, L. M. and Jensen, G. S. (1992) Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am, 6, pp. 297-322.
13. Bergsagel, P., Smith, A., Szczepek, A., Mant, M., Belch, A. and Pilarski, L. (1995) In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood, 85, pp. 436-447.
14. Moreau, P., Voillat, L., Benboukher, L., Mathiot, C., Dumontet, C. and Robillard, N. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia, 21, pp. 835-836.
15. Jacobson, J. L., Hussein, M. A., Barlogie, B., Durie, B. G. and Crowley, J. J. (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol, 122, pp. 441-450.
16. Greipp, P. R., Leong, T., Bennett, J. M., Gaillard, J. P., Klein, B. and Stewart, J. A. (1998) Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood, 91, pp. 2501-2507.
17. Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D. and Schlossman, R. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-Cell malignancies. J Immunother, 24, pp. 263-271.
18. Musto, P., Carella Jr, A. M., Greco, M. M., Falcone, A., Sanpaolo, G. and Bodenizza, C. (2003) Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol, 123, pp. 746-747.